| 推广-MedSci.cn - 梅斯(MedSci)
Baidu
map

三大致盲性眼病:白内障、青光眼和黄斑变性,记住三句话,别等失明才后悔!| 推广

2017-11-09 佚名 健康时报

数据显示,每5个盲人当中,有4人的视力损伤是可以避免的。全球2.8亿视力受损患者中,80%的因素是可以预防的。



数据显示,每5个盲人当中,有4人的视力损伤是可以避免的。全球2.8亿视力受损患者中,80%的因素是可以预防的。

世界卫生组织(WHO)认定的三大致盲性眼病——白内障、青光眼和黄斑变性,在我国依然横行。北京协和医院眼科赵家良教授提到,我国部分地区由于文化程度低,白内障依然没有得到很好的治疗。又由于认知程度低,高度近视引起的眼底病变以及老年人黄斑变性、糖尿病视网膜病变等也正在成为重要的致盲因素。

1、青光眼是世界首位的不可逆性致盲眼病

青光眼因其不可逆性,其影响比白内障还严重。预计到2020年,我国将有2100万的青光眼患者。

很多人认为青光眼是老人病,事实上,青光眼在任何年龄段的人群均可发病,从刚出生的婴儿直到耄耋之年的老人都会罹患此病。

青光眼主要有以下三类:
1、急性发作
眼球内压力急剧升高,患者会感觉到头痛,眼痛,这类患者如果不迅速把眼压控制到正常水平,在短时间内就可致盲;

2、慢性眼压升高
这些患者就没有明显的症状,同时还保持较好的视力,但是视野在不断的缩小,等患者有症状的时候,已经到了视神经损害的晚期;

3、发生在婴幼儿的青光眼
主要表现为婴儿出生后眼球大于正常孩子,怕光,流泪,确诊后要尽快手术才有可能保留一定的视觉功能。
北京协和医院赵家良教授在诺华张江园区的一场关于中国眼科发展30年的交流研讨会上称,青光眼如果能早期发现、合理治疗,将眼压控制在一定水平,可以终生不失明。有家族史的人青光眼发病率更高,如果医生能做到关注患者家属,定期检查,将能拯救更多青光眼患者。

2、预防黄斑变性,用眼切忌目不转睛


预防眼底黄斑病变,要明确几个引发病变的危险因素,除了年龄外,性别(研究显示女性可能患此病的倾向是男性的2倍)、吸烟、长期暴露于阳光下、营养不良,如胡萝卜素水平较低、体内叶黄素含量较低等,都会引发眼底黄斑病变。

早期预防眼底黄斑病变,首先要从用眼习惯入手,用眼时切忌“目不转睛”,可以常做眨眼,以减少眼球暴露于空气中的时间,避免泪液蒸发,同时要尽量减少长时间连续操作电脑,注意中间休息,通常连续操作1小时,休息5~10分钟。

3、白内障盯上年轻人,三个信号别大意

很多年轻人白天伏案工作,下班了也手机不离手,聊天、游戏、网购。电脑手机等屏幕的辐射对眼睛的伤害很大,是白内障的诱因之一。一些年轻人还喜欢拿着手机看电子小说、发短信,不管在公共汽车上还是睡前躺着看,都对眼睛不利。舞厅、酒吧,一明一暗急速变换的灯光对眼睛也有影响。

要特别注意这些早起发病的信号,尽早去医院检查治疗


1、视力下降。近视眼度数急速升高;远视眼却会发现,度数降低了,不戴远视眼镜也能阅读,这种现象称为第二视力,都是屈光改变,白内障的早期症状。

2、明亮的光线下视力更差,这是由于明亮光照射,瞳孔缩小,眼睛的光通道变窄的原因。

3、看物体会出现重影、虚影,这是由于晶状体肿胀,视物变形,出现单眼复视或多视造成。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1810903, encodeId=8d3a181090347, content=<a href='/topic/show?id=1c9c86522b1' target=_blank style='color:#2F92EE;'>#致盲性眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86522, encryptionId=1c9c86522b1, topicName=致盲性眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Wed Dec 20 09:13:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463573, encodeId=76d514635e317, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525107, encodeId=2718152510ec8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540502, encodeId=936b15405029a, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587355, encodeId=b89c158e355df, content=<a href='/topic/show?id=7e9a56e67a0' target=_blank style='color:#2F92EE;'>#推广#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56767, encryptionId=7e9a56e67a0, topicName=推广)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dff417466583, createdName=zhangxingru, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1810903, encodeId=8d3a181090347, content=<a href='/topic/show?id=1c9c86522b1' target=_blank style='color:#2F92EE;'>#致盲性眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86522, encryptionId=1c9c86522b1, topicName=致盲性眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Wed Dec 20 09:13:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463573, encodeId=76d514635e317, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525107, encodeId=2718152510ec8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540502, encodeId=936b15405029a, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587355, encodeId=b89c158e355df, content=<a href='/topic/show?id=7e9a56e67a0' target=_blank style='color:#2F92EE;'>#推广#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56767, encryptionId=7e9a56e67a0, topicName=推广)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dff417466583, createdName=zhangxingru, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2017-11-11 huangdf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1810903, encodeId=8d3a181090347, content=<a href='/topic/show?id=1c9c86522b1' target=_blank style='color:#2F92EE;'>#致盲性眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86522, encryptionId=1c9c86522b1, topicName=致盲性眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Wed Dec 20 09:13:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463573, encodeId=76d514635e317, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525107, encodeId=2718152510ec8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540502, encodeId=936b15405029a, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587355, encodeId=b89c158e355df, content=<a href='/topic/show?id=7e9a56e67a0' target=_blank style='color:#2F92EE;'>#推广#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56767, encryptionId=7e9a56e67a0, topicName=推广)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dff417466583, createdName=zhangxingru, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2017-11-11 muzishouyi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1810903, encodeId=8d3a181090347, content=<a href='/topic/show?id=1c9c86522b1' target=_blank style='color:#2F92EE;'>#致盲性眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86522, encryptionId=1c9c86522b1, topicName=致盲性眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Wed Dec 20 09:13:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463573, encodeId=76d514635e317, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525107, encodeId=2718152510ec8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540502, encodeId=936b15405029a, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587355, encodeId=b89c158e355df, content=<a href='/topic/show?id=7e9a56e67a0' target=_blank style='color:#2F92EE;'>#推广#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56767, encryptionId=7e9a56e67a0, topicName=推广)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dff417466583, createdName=zhangxingru, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2017-11-11 pps20023
  5. [GetPortalCommentsPageByObjectIdResponse(id=1810903, encodeId=8d3a181090347, content=<a href='/topic/show?id=1c9c86522b1' target=_blank style='color:#2F92EE;'>#致盲性眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86522, encryptionId=1c9c86522b1, topicName=致盲性眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Wed Dec 20 09:13:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463573, encodeId=76d514635e317, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525107, encodeId=2718152510ec8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540502, encodeId=936b15405029a, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587355, encodeId=b89c158e355df, content=<a href='/topic/show?id=7e9a56e67a0' target=_blank style='color:#2F92EE;'>#推广#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56767, encryptionId=7e9a56e67a0, topicName=推广)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dff417466583, createdName=zhangxingru, createdTime=Sat Nov 11 13:13:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

相关资讯

Free Radic Biol Med:研究人员揭示与白内障形成相关的晶状体蛋白质变化!

晶状体由晶状体囊和晶状体纤维组成,是一个双凸面透明组织,被悬韧带固定悬挂在虹膜之后玻璃体之前,是眼球中重要的屈光间质之一,当晶状体代谢紊乱时,会导致晶状体蛋白质变性而发生混浊,称为白内障。

Lancet Global Health:全球视力障碍及失明因素分析——1990-2020

研究发现,随着人口和年龄的增长,视力异常患者人数急剧增加。对于50岁以上人群,白内障和屈光不正是导致失明和中重度视力障碍的主要因素

残疾预防:从“早发现、早诊断、早干预”开始

8月25日是我国首个“残疾预防日”。根据第二次全国残疾人抽样调查推算,我国残疾人每年增加约200万人。专家认为,残疾预防,关键在“早发现、早诊断、早干预”。根据中国残疾人事业统计资料,2014年度新办证残疾人229.3万人,主要致残原因有:视力残疾(视网膜色素膜病变、白内障)、听力残疾(老年性耳聋)、言语残疾(听力障碍)、肢体残疾(外伤、脑血管疾病、骨关节病)、智力残疾(脑疾病)、精神残疾(精神分

Eur J Ophthalmol:移动飞秒激光平台用于儿科白内障手术!

英国康乃尔眼科医院心脏外科疾病系的Fung SSM近日在Eur J Ophthalmol杂志上发表了他们近期的一项工作,他们介绍了移动飞秒激光平台在辅助小儿白内障手术中的应用。

Ophthalmology:似曾相识的罕见并发症--HORV

2007年欧洲白内障与屈光手术协会(ESCRS)公布一项前瞻性多中心随机对照试验结果:白内障术中常规前房内注射头孢呋辛可5倍降低术后眼内炎发生率。这一结果使白内障术中抗生素预防性应用由2007年30%攀升至2014年50%,因美国缺少眼内头孢呋辛处方用药,万古霉素则成为术中常用预防性抗生素。

Baidu
map
Baidu
map
Baidu
map